Palliative Systemic Therapy Given near the End of Life for Metastatic Non-Small Cell Lung Cancer.
Marc-Étienne BeaudetYves LacasseCatherine LabbéPublished in: Current oncology (Toronto, Ont.) (2022)
In this retrospective cohort of patients with metastatic NSCLC, 22% of patients received SACT within 30 days of death, with a negative impact on access to PC, higher rates of in hospital death, decreased use of MAiD and palliative sedation, and a shorter median OS.
Keyphrases
- small cell lung cancer
- end stage renal disease
- palliative care
- ejection fraction
- newly diagnosed
- chronic kidney disease
- squamous cell carcinoma
- healthcare
- prognostic factors
- peritoneal dialysis
- cross sectional
- emergency department
- intensive care unit
- bone marrow
- cell therapy
- mesenchymal stem cells
- adverse drug
- acute care
- brain metastases